首页> 外文期刊>Experimental & molecular medicine. >Differentiated miRNA expression and validation of signaling pathways in apoE gene knockout mice by cross-verification microarray platform
【24h】

Differentiated miRNA expression and validation of signaling pathways in apoE gene knockout mice by cross-verification microarray platform

机译:交叉验证微阵列平台在apoE基因敲除小鼠中差异化的miRNA表达和信号通路的验证

获取原文
           

摘要

The microRNA (miRNA) regulation mechanisms associated with atherosclerosis are largely undocumented. Specific selection and efficient validation of miRNA regulation pathways involved in atherosclerosis development may be better assessed by contemporary microarray platforms applying cross-verification methodology. A screening platform was established using both miRNA and genomic microarrays. Microarray analysis was then simultaneously performed on pooled atherosclerotic aortic tissues from 10 Apolipoprotein E (apoE) knockout mice (apoE?/?) and 10 healthy C57BL/6 (B6) mice. Differentiated miRNAs were screened and cross-verified against an mRNA screen database to explore integrative mRNA–miRNA regulation. Gene set enrichment analysis was conducted to describe the potential pathways regulated by these mRNA–miRNA interactions. High-throughput data analysis of miRNA and genomic microarrays of knockout and healthy control mice revealed 75 differentially expressed miRNAs in apoE?/? mice at a threshold value of 2. The six miRNAs with the greatest differentiation expression were confirmed by real-time quantitative reverse-transcription PCR (qRT–PCR) in atherosclerotic tissues. Significantly enriched pathways, such as the type 2 diabetes mellitus pathway, were observed by a gene-set enrichment analysis. The enriched molecular pathways were confirmed through qRT–PCR evaluation by observing the presence of suppressor of cytokine signaling 3 (SOCS3) and SOCS3-related miRNAs, miR-30a, miR-30e and miR-19b. Cross-verified high-throughput microarrays are optimally accurate and effective screening methods for miRNA regulation profiles associated with atherosclerosis. The identified SOCS3 pathway is a potentially valuable target for future development of targeted miRNA therapies to control atherosclerosis development and progression.
机译:与动脉粥样硬化相关的microRNA(miRNA)调节机制在很大程度上尚无记载。通过使用交叉验证方法的当代微阵列平台,可以更好地评估与动脉粥样硬化发展有关的miRNA调控途径的特异性选择和有效验证。使用miRNA和基因组微阵列建立了筛选平台。然后同时对来自10只载脂蛋白E(apoE)基因敲除小鼠(apoEα/β)和10只健康C57BL / 6(B6)小鼠的合并的动脉粥样硬化主动脉组织进行微阵列分析。筛选分化的miRNA,并针对mRNA筛选数据库进行交叉验证,以探索整合的mRNA–miRNA调控。进行了基因集富集分析,以描述由这些mRNA-miRNA相互作用调节的潜在途径。基因敲除小鼠和健康对照小鼠的miRNA和基因组微阵列的高通量数据分析显示apoEβ/β中75种差异表达的miRNA。小鼠的阈值为2。通过实时定量逆转录PCR(qRT–PCR)在动脉粥样硬化组织中确认了分化表达最大的6个miRNA。通过基因集富集分析观察到了显着富集的途径,例如2型糖尿病途径。通过观察细胞因子信号传导抑制因子3(SOCS3)和与SOCS3相关的miRNA,miR-30a,miR-30e和miR-19b的存在,通过qRT-PCR评估确认了丰富的分子途径。交叉验证的高通量微阵列是与动脉粥样硬化相关的miRNA调控谱的最佳准确和有效筛选方法。所确定的SOCS3途径对于控制miRNA动脉粥样硬化发展和进程的靶向miRNA疗法的未来发展可能具有潜在的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号